{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T09:17:51Z","timestamp":1717751871991},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,2,4]],"date-time":"2014-02-04T00:00:00Z","timestamp":1391472000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"published-print":{"date-parts":[[2014,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Activated vitamin D is the mainstay of treatment for secondary hyperparathyroidism (SHPT) in chronic hemodialysis patients. However, the optimal route of administration is still debated. The aim of our study was to compare efficacy of oral <jats:italic>vs<\/jats:italic> intravenous (IV) administration of alfacalcidol in hemodialysis. A secondary objective was to determine the cost-effectiveness advantage of oral administration.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Eighty-eight chronic hemodialysis patients receiving IV alfacalcidol three times a week were included in the study. All were switched to the same dose of alfacalcidol given orally three times a week during the hemodialysis session. A budget impact analysis was performed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Mean patient age was 64\u00a0years old and 43% were males. The mean alfacalcidol dose administered was 2.1\u00a0\u03bcg three times a week. After three months, serum parathormone (PTH) levels decreased from 80 to 59 pmol\/L (p =\u20090.001) and total serum calcium levels increased from 2.34 to 2.40\u00a0mmol\/L (p =\u20090.002). After six months, total serum calcium levels were still significantly higher. Alfacalcidol dosage was significantly decreased during study period; the mean reduction was 0.44\u00a0\u03bcg per dose. Finally, oral administration was associated with an annual cost reduction of 197 678$CAN and an annual nursing time reduction of 25\u00a0days.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Our findings support that switching IV to oral administration of alfacalcidol during hemodialysis sessions may lead to a similar control of SHPT with lower doses of activated vitamin D. This is a good strategy for optimizing compliance and may allow a dose reduction because of a greater efficacy to suppress PTH. Oral administration also has significant cost-effectiveness advantages.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1471-2369-15-27","type":"journal-article","created":{"date-parts":[[2014,2,4]],"date-time":"2014-02-04T10:02:47Z","timestamp":1391508167000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Comparison of oral and intravenous Alfacalcidol in chronic hemodialysis patients"],"prefix":"10.1186","volume":"15","author":[{"given":"Myriam","family":"Lessard","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denis","family":"Ouimet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martine","family":"Leblanc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annie-Claire","family":"Nadeau-Fredette","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Bell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Philippe","family":"Lafrance","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Pichette","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel","family":"Vall\u00e9e","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,2,4]]},"reference":[{"issue":"3","key":"721_CR1","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1681\/ASN.V73488","volume":"7","author":"BS Levine","year":"1996","unstructured":"Levine BS, Song M: Pharmacokinetics and efficacy of pulse oral versus intravenous calcitriol in hemodialysis patients. J Am Soc Nephrol. 1996, 7 (3): 488-496.","journal-title":"J Am Soc Nephrol"},{"key":"721_CR2","doi-asserted-by":"publisher","first-page":"50","DOI":"10.2215\/CJN.03940510","volume":"6","author":"P Kandula","year":"2011","unstructured":"Kandula P, Dobre M, Schold JD, et al: Vitamin D supplementation in chronic kidney disease: a systematic review and meta-analysis of observational studies and randomized controlled trials. Clin J Am Soc Nephrol. 2011, 6: 50-62. 10.2215\/CJN.03940510.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"721_CR3","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1093\/ndt\/gfg017","volume":"18","author":"AF Costa","year":"2003","unstructured":"Costa AF, dos Reis LM, Ribeiro MC, Moys\u00e9s RM, Jorgetti V: Effects of calcitriol on parathyroid function and on bone remodelling in secondary hyperparathyroidism. Nephrol Dial Transplant. 2003, 18 (4): 743-749. 10.1093\/ndt\/gfg017.","journal-title":"Nephrol Dial Transplant"},{"issue":"11","key":"721_CR4","doi-asserted-by":"publisher","first-page":"3662","DOI":"10.1093\/ndt\/gfn264","volume":"23","author":"M Taniguchi","year":"2008","unstructured":"Taniguchi M, Tokumoto M, Tsuruya K, Hirakata H, Iida M: Intravenous calcitriol therapy in an early stage prevents parathyroid gland growth. Nephrol Dial Transplant. 2008, 23 (11): 3662-3669. 10.1093\/ndt\/gfn264.","journal-title":"Nephrol Dial Transplant"},{"issue":"8","key":"721_CR5","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/ki.2011.260","volume":"80","author":"R Kumar","year":"2011","unstructured":"Kumar R: New clinical trials with vitamin D and analogs in renal disease. Kidney Int. 2011, 80 (8): 793-796. 10.1038\/ki.2011.260.","journal-title":"Kidney Int"},{"issue":"3","key":"721_CR6","first-page":"97","volume":"20","author":"HH Liou","year":"1994","unstructured":"Liou HH, Chiang SS, Huang TP, Shieh SD, Akmal M: Comparative effect of oral or intravenous calcitriol on secondary hyperparathyroidism in chronic hemodialysis patients. Miner Electrolyte Metab. 1994, 20 (3): 97-102.","journal-title":"Miner Electrolyte Metab"},{"issue":"2","key":"721_CR7","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1159\/000049041","volume":"90","author":"S Turk","year":"2002","unstructured":"Turk S, Akbulut M, Yildiz A, et al: Comparative effect of oral pulse and intravenous calcitriol treatment in hemodialysis patients: The effect on serum IL-1 and IL-6 levels and bone mineral density. Nephron. 2002, 90 (2): 188-194. 10.1159\/000049041.","journal-title":"Nephron"},{"issue":"6","key":"721_CR8","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1177\/147323000303100604","volume":"31","author":"A Borazan","year":"2003","unstructured":"Borazan A, Ustun H, Cefle A, Sekitmez N, Yilmaz A: Comparative efficacy of oral and intravenous calcitriol treatment in haemodialysis patients: Effects on serum biochemistry and cytokine levels. J Int Med Res. 2003, 31 (6): 489-496. 10.1177\/147323000303100604.","journal-title":"J Int Med Res"},{"issue":"3","key":"721_CR9","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1159\/000190286","volume":"77","author":"G Bacchini","year":"1997","unstructured":"Bacchini G, Fabrizi F, Pontoriero G, Marcelli D, di Filippo S, Locatelli F: \u201cPulse oral\u201d versus intravenous calcitriol therapy in chronic hemodialysis patients: a prospective and randomized study. Nephron. 1997, 77 (3): 267-272. 10.1159\/000190286.","journal-title":"Nephron"},{"issue":"12","key":"721_CR10","doi-asserted-by":"publisher","first-page":"840","DOI":"10.7326\/0003-4819-147-12-200712180-00004","volume":"147","author":"SC Palmer","year":"2007","unstructured":"Palmer SC, McGregor DO, Macaskill P, Craig JC, Elder GJ, Strippoli GF: Meta-analysis: vitamin D compounds in chronic kidney disease. Ann Intern Med. 2007, 147 (12): 840-853. 10.7326\/0003-4819-147-12-200712180-00004.","journal-title":"Ann Intern Med"},{"issue":"6","key":"721_CR11","doi-asserted-by":"publisher","first-page":"415","DOI":"10.5414\/CNP65415","volume":"65","author":"F Tarrass","year":"2006","unstructured":"Tarrass F, Yazidi A, Sif H, Zamd M, Benghanem MG, Ramdani B: A randomized trial of intermittent versus continuous oral alfacalcidol treatment of hyperparathyroidism in end-stage renal disease. Clin Nephrol. 2006, 65 (6): 415-418. 10.5414\/CNP65415.","journal-title":"Clin Nephrol"},{"issue":"3","key":"721_CR12","doi-asserted-by":"publisher","first-page":"276","DOI":"10.5414\/CNP71276","volume":"71","author":"H Zhou","year":"2009","unstructured":"Zhou H, Xu C: Comparison of intermittent intravenous and oral calcitriol in the treatment of secondary hyperparathyroidism in chronic hemodialysis patients: a meta-analysis of randomized controlled trials. Clin Nephrol. 2009, 71 (3): 276-285. 10.5414\/CNP71276.","journal-title":"Clin Nephrol"},{"issue":"5","key":"721_CR13","doi-asserted-by":"publisher","first-page":"319","DOI":"10.5414\/CNP59319","volume":"59","author":"RB Mazess","year":"2003","unstructured":"Mazess RB, Elangovan L: A review of intravenous versus oral vitamin D hormone therapy in hemodialysis patients. Clin Nephrol. 2003, 59 (5): 319-325. 10.5414\/CNP59319.","journal-title":"Clin Nephrol"},{"issue":"2","key":"721_CR14","first-page":"174","volume":"11","author":"AH Mitwalli","year":"2000","unstructured":"Mitwalli AH, Alam AA: Intermittent oral versus intravenous alfacalcidol in dialysis patients. Saudi J Kidney Dis Transpl. 2000, 11 (2): 174-180.","journal-title":"Saudi J Kidney Dis Transpl"},{"issue":"2","key":"721_CR15","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1081\/JDI-200049538","volume":"27","author":"Y Gu","year":"2005","unstructured":"Gu Y, Ding F, Chen N, et al: Comparisons between oral pulse alfacalcidol therapy and daily therapy in maintenance hemodialysis patients with secondary hyperparathyroidism: a randomized, controlled, and multicenter study. Ren Fail. 2005, 27 (2): 205-212. 10.1081\/JDI-49538.","journal-title":"Ren Fail"},{"key":"721_CR16","first-page":"S1","volume":"113","author":"Kidney Disease: Improving Global Outcome (KDIGO) CKD-MBD Work Group","year":"2009","unstructured":"Kidney Disease: Improving Global Outcome (KDIGO) CKD-MBD Work Group: KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int. 2009, 113: S1-S130.","journal-title":"Kidney Int"},{"issue":"2","key":"721_CR17","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/j.1542-4758.2011.00531.x","volume":"15","author":"M Pettigrew","year":"2011","unstructured":"Pettigrew M, Soltys GIM, Bell RZ, et al: Tinzaparin reduces health care resource use for anticoagulation in hemodialysis. Hemodial Int. 2011, 15 (2): 273-279. 10.1111\/j.1542-4758.2011.00531.x.","journal-title":"Hemodial Int"},{"issue":"3","key":"721_CR18","first-page":"332","volume":"59","author":"YT Pena","year":"2010","unstructured":"Pena YT, Soyibo AK, Mc Growder D, Clarke TR, Barton EN: The importance of bone biomarkers in the diagnosis of renal osteodystrophy. West Indian Med J. 2010, 59 (3): 332-337.","journal-title":"West Indian Med J"},{"issue":"3","key":"721_CR19","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1111\/j.1440-1797.2010.01398.x","volume":"16","author":"K Kiattisunthorn","year":"2011","unstructured":"Kiattisunthorn K, Wutyam K, Indranoi A, Vasuvattakul S: Randomized trial comparing pulse calcitriol and alfacalcidol for the treatment of secondary hyperparathyroidism in haemodialysis patients. Nephrology. 2011, 16 (3): 277-284. 10.1111\/j.1440-1797.2010.01398.x.","journal-title":"Nephrology"},{"issue":"1","key":"721_CR20","first-page":"e36","volume":"15","author":"S Moe","year":"2008","unstructured":"Moe S, Wazny LD, Martin JE: Oral calcitriol versus oral alfacalcidol for the treatment of secondary hyperparathyroidism in patients receiving hemodialysis: a randomized, crossover trial. Can J Clin Pharmacol. 2008, 15 (1): e36-e43.","journal-title":"Can J Clin Pharmacol"},{"issue":"2","key":"721_CR21","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1111\/j.1744-9987.2008.00559.x","volume":"12","author":"N Al-Hilali","year":"2008","unstructured":"Al-Hilali N, Al-Humoud H, Al-Helal B, Al-Azmi M, Al-Kandari NH, Johny KV: Intravenous alfacalcidol once weekly suppresses parathyroid hormone in hemodialysis patients. Ther Apher Dial. 2008, 12 (2): 137-142. 10.1111\/j.1744-9987.2008.00559.x.","journal-title":"Ther Apher Dial"},{"issue":"3","key":"721_CR22","doi-asserted-by":"publisher","first-page":"329","DOI":"10.3109\/0886022X.2011.560408","volume":"33","author":"EM El-Shafey","year":"2011","unstructured":"El-Shafey EM, Alsahow AE, El-Nagar GF, Ezzat A: Intravenous alfacalcidol once weekly pulse therapy for secondary hyperparathyroidism in hemodialysis patients. Ren Fail. 2011, 33 (3): 329-333. 10.3109\/0886022X.2011.560408.","journal-title":"Ren Fail"},{"issue":"Suppl 29","key":"721_CR23","first-page":"S54","volume":"38","author":"JW Coburn","year":"1990","unstructured":"Coburn JW: Use of oral and parenteral calcitriol in the treatment of renal osteodystrophy. Kidney Int. 1990, 38 (Suppl 29): S54-S61.","journal-title":"Kidney Int"},{"issue":"1","key":"721_CR24","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1159\/000186210","volume":"57","author":"Y Tsukamoto","year":"1991","unstructured":"Tsukamoto Y, Nomura M, Takahashi Y, et al: The \u201coral 1,25 dihydroxyvitamin D3 pulse therapy\u201d in hemodialysis patients with severe secondary hyperparathyroidism. Nephron. 1991, 57 (1): 23-28. 10.1159\/000186210.","journal-title":"Nephron"},{"issue":"6","key":"721_CR25","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1038\/ki.1994.223","volume":"45","author":"LD Quarles","year":"1994","unstructured":"Quarles LD, Yohay DA, Carroll BA, et al: Prospective trial of pulse oral versus intravenous calcitriol treatment of hyperparathyroidism in ESRD. Kidney Int. 1994, 45 (6): 1710-1721. 10.1038\/ki.1994.223.","journal-title":"Kidney Int"},{"issue":"3","key":"721_CR26","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/BF00866773","volume":"10","author":"LD Quarles","year":"1996","unstructured":"Quarles LD, Indridason OS: Calcitriol administration in end-stage renal disease: intravenous or oral?. Pediatr Nephrol. 1996, 10 (3): 331-336. 10.1007\/BF00866773.","journal-title":"Pediatr Nephrol"},{"issue":"4","key":"721_CR27","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1097\/00041552-199507000-00004","volume":"4","author":"OS Indridason","year":"1995","unstructured":"Indridason OS, Quarles LD: Oral versus intravenous calcitriol: is the route of administration really important?. Curr Opin Nephrol Hypertens. 1995, 4 (4): 307-312. 10.1097\/00041552-199507000-00004.","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"5 Suppl 5","key":"721_CR28","doi-asserted-by":"publisher","first-page":"S41","DOI":"10.1053\/ajkd.2001.28108","volume":"38","author":"DL Andress","year":"2001","unstructured":"Andress DL: Intravenous versus oral vitamin D therapy in dialysis patients: what is the question?. Am J Kidney Dis. 2001, 38 (5 Suppl 5): S41-S44.","journal-title":"Am J Kidney Dis"},{"key":"721_CR29","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1161\/01.CIR.75.1.265","volume":"75","author":"M Talajic","year":"1987","unstructured":"Talajic M, DeRoode MR, Nattel S: Comparative electrophysiologic effects of intravenous amiodarone and desethylamiodarone in dogs: evidence for clinically relevant activity of the metabolite. Circulation. 1987, 75: 265-271. 10.1161\/01.CIR.75.1.265.","journal-title":"Circulation"},{"issue":"6","key":"721_CR30","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1177\/106002809603000612","volume":"30","author":"MS Chow","year":"1996","unstructured":"Chow MS: Intravenous amiodarone: pharmacology, pharmacokinetics, and clinical use. Ann Pharmacother. 1996, 30 (6): 637-643.","journal-title":"Ann Pharmacother"},{"issue":"5","key":"721_CR31","first-page":"397","volume":"13","author":"MS Joy","year":"2007","unstructured":"Joy MS, Karagiannis PC, Peyerl FW: Outcomes of secondary hyperparathyroidism in chronic kidney disease and the direct costs of treatment. J Manag Care Pharm. 2007, 13 (5): 397-411.","journal-title":"J Manag Care Pharm"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2369-15-27.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2369-15-27\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2369-15-27","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2369-15-27.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T02:59:58Z","timestamp":1630551598000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/1471-2369-15-27"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2,4]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["721"],"URL":"https:\/\/doi.org\/10.1186\/1471-2369-15-27","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,2,4]]},"assertion":[{"value":"24 April 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"27"}}